Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.
about
Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinantSCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3aPredictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study.Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C.Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.HCV genetic variability: from quasispecies evolution to genotype classification.Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line.Hepatitis C virus genetic variability and evolution.Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly.An artificial neural network approach to the drug efficacy of interferon treatments.Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.Inhibition of the replication of a hepatitis C virus-like RNA template by interferon and 3'-deoxycytidine.Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C.Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy.Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy.2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection.A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy.Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C.Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C.
P2860
Q24814549-7803D38A-FE1C-455C-B3B8-47109906DD2EQ27473129-62EEC611-1D1E-4131-961F-B824CE87A08EQ27486521-DF948934-402F-423D-8FED-695770ADEFD9Q27490866-E385CBE6-8F38-4B3A-833E-665726F81AD1Q34304221-B8985794-3547-49DE-A153-C59F7CEBA660Q34395035-F62ED094-2B7A-4253-BC15-6CC4ED419BE7Q37243555-A42FD5BC-E1FA-4767-BD06-395B622E4B8AQ37425275-F6A75B9B-C346-4948-8EEB-1A2B549F7991Q37604941-EEFEBAF3-4D3B-4B73-9214-74861455D790Q38456906-AD8E9938-255A-4EC9-BE1B-01C9BD3FF7C7Q38970639-386BECE5-4117-4786-A4BD-46576960D54CQ39756099-87B4F01D-AA53-4338-91FF-F627493A3F58Q40277321-B013AC55-660C-4060-8942-35A96AD9EA42Q40547796-0DBA74B1-63FA-4799-8DFC-749B1BCB38A0Q40651771-EC97BEBA-C90C-47ED-A40B-7CD2AB437E13Q41039294-F019E3D1-1F6E-4F12-B378-53624B8100C7Q42518584-05055FC0-61BE-43C7-9126-037B368B01BDQ42988918-77677010-5A5A-46C8-B929-CC4A4E31E99EQ42992069-280CADDC-AC62-43BE-BD7A-61C662A36FA5Q42992776-BA40F905-0FA3-4F1F-8164-179820C04F26Q43031195-15745377-7F7E-451D-8E09-DFD7CAAFB7B1Q43036608-9002EAAA-FF8B-4EB9-81B6-0D99FBC2F1B0Q43039954-5799A989-091A-4E59-9CB6-DE271B9A4467Q43047613-71F1E4A0-9B20-4266-AAEC-66B3A9C67D66Q46584613-FE484389-F2BB-49C0-A71A-50B36E0696C0Q50569876-ED94B655-9E11-400D-AB02-5982864C66ECQ50571978-994BA67B-0A75-43CD-9913-EE7F18DB708E
P2860
Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@ast
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@en
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@nl
type
label
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@ast
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@en
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@nl
prefLabel
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@ast
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@en
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@nl
P2093
P2860
P1476
Viral, host and interferon-rel ...... r hepatitis C virus infection.
@en
P2093
P2860
P356
10.1046/J.1365-2893.2001.00253.X
P577
2001-01-01T00:00:00Z